Houman Alimoradi, Khaled Greish*, Allan B. Gamble and Gregory I. Giles* Pages 279 - 303 ( 25 )
Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.
Cancer therapy, controlled delivery, nanoparticles, nitric oxide donors, nitric oxide releasing biomaterials, nitric oxide.
Department of Pharmacology and Toxicology, University of Otago, Dunedin, Department of Molecular Medicine, and Nanomedicine Unit, Princess Al-Jawhara Centre for Molecular Medicine and inherited disorders, College of Medicine and Medical sciences, Arabian Gulf University, Manama, School of Pharmacy, University of Otago, Dunedin, Department of Pharmacology and Toxicology, University of Otago, Dunedin